A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
October 3, 2017
End Date
September 17, 2020
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
October 3, 2017
End Date
September 17, 2020